Samuel is a pluripotent stem cell biologist and tissue engineer with experience in retinal and hepatic cell therapies. When joining Dark Horse Consulting in 2021, he brought more than a decade of experience in working with pluripotent stem cells. In his role as a DHC consultant, Samuel regularly advises clients on nonclinical development and strategy, including interactions with regulators, across all stages of drug product development. Moreover, Samuel provides clients with technical writing expertise to support the authoring of both study reports and regulatory submissions.
In his role as a consultant at Dark Horse Consulting, Samuel regularly advices clients on nonclinical development and strategy, including interactions with regulators, across all stages of drug product development. Moreover, Samuel provides clients with technical writing expertise to support the authoring of both study reports and regulatory submissions.
Samuel first began working with pluripotent stem cells as an undergraduate student where he successfully derived embryonic stem cell lines from genetic mouse models. This research experience motivated him to undertake a dedicated master’s degree in stem cell technologies and to then gain further research experience within Professor Robin Ali’s cell and gene therapy lab at University College London.
While at UCL, he gained experience in 3D differentiation within bioreactors, virus production and cell transplantation. Samuel then moved to King’s College London to undertake an mRes degree where he gained experience in fabricating natural/synthetic biomaterials, isolation & culture of primary human hepatocytes, and hiPSC-derived organoid culture.
During his doctoral studies at King’s he established SOPs for the culture and differentiation of cGMP-compliant human pluripotent stem cells into hepatocytes. Moreover, he published a proof-of-concept study demonstrating the transplantation feasibility of encapsulated 3D cell constructs for treating liver failure. Additionally, Samuel’s doctorial work also focused on utilizing the physical properties of tunable synthetic biomaterials to improve the differentiation of cGMP-compliant cells. Samuel also gained experience in automated high through-put screening/imaging to identify novel compounds to enhance cellular differentiation. After finishing these studies, he has been involved in academia to industry tech transfer of cell culture protocols and cell product characterization assays. Most recently Samuel’s work has focused on producing disease models for inherited metabolic diseases and viral infections.